Yusuf Yesil, MD, MIS 
Molecular testing determines who receives targeted therapy, but standard next-generation sequencing suffers from two persistent flaws: it takes weeks and consumes precious tissue samples. Deep learning models reading routine hematoxylin and eosin (H&E)-stained slides bypass both bottlenecks by screening for actionable genomic alterations at initial diagnosis.
This approach shifts AI from an experimental diagnostic tool to a clinical triage layer. Rather than replacing comprehensive sequencing, image-based prediction screens patients instantly to prioritize rapid testing or clinical trial enrollment.
That immediate triage is the real story.
From Slides to Gene Targets
Algorithms no longer just classify tissue structures or segment cell nuclei. Building on foundational work in pan-cancer computational histopathology, modern models infer specific gene mutations directly from morphological patterns in standard glass slides.
Prospective evidence now validates this approach across global patient populations:
- EGFR alterations in non-small cell lung cancer identified in prospective validation through the landmark EAGLE trial.
- FGFR alterations in urothelial cancer accurately flagged in prospective cohorts within the ANNAR trial.
- Near-instant digital prediction operating without consuming additional tissue or requiring specialized molecular reagents.
Earlier computational models focused primarily on tissue segmentation or microenvironment profiling, such as deep learning for tumor microenvironments. The latest clinical prospective trials move past spatial analysis to deliver direct genomic predictions that guide oncologists toward specific drugs.
The Clinical Triage Shift
Tissue exhaustion causes major delays in precision oncology. When initial biopsies yield insufficient material for genomic panels, patients face repeat biopsies or delayed treatment decisions. Routine slide-based AI screening ensures every standard diagnostic stain doubles as an immediate molecular triage step.
This setup does not eliminate genomic sequencing. Instead, it alters patient management by identifying high-probability candidates instantly, allowing clinicians to order focused confirmatory assays or reserve enrollment slots in precision trials while comprehensive panels run in the background.
That speed changes clinical workflow entirely.
Implementation Limits and Next Steps
Despite prospective trial success, slide-based AI remains an indirect surrogate for genomic sequencing. False negatives could delay optimal targeted therapies if clinicians rely on image screens to rule out mutations without follow-up sequencing.
Variations in slide staining, scanner hardware, and pre-analytical tissue processing across global laboratories also introduce potential performance drift. Image-based prediction serves best as an immediate enrichment tool for sequencing workflows, not an independent replacement for DNA sequencing.
Pathology departments should evaluate these models as non-destructive diagnostic triaging tools to reduce turnaround times and preserve biopsy specimens.
Read the full perspective in npj Precision Oncology.
